United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System increased its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 13.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 74,022 shares of the biotechnology company’s stock after acquiring an additional 9,007 shares during the quarter. State Board of Administration of Florida Retirement System owned about 0.17% of United Therapeutics worth $8,376,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Legacy Financial Advisors Inc. acquired a new position in shares of United Therapeutics during the second quarter worth about $107,000. NuWave Investment Management LLC boosted its position in shares of United Therapeutics by 13,112.5% during the first quarter. NuWave Investment Management LLC now owns 1,057 shares of the biotechnology company’s stock worth $116,000 after buying an additional 1,049 shares during the period. HL Financial Services LLC boosted its position in shares of United Therapeutics by 40.2% during the first quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock worth $231,000 after buying an additional 589 shares during the period. Trexquant Investment LP acquired a new position in United Therapeutics during the first quarter valued at approximately $266,000. Finally, Fox Run Management L.L.C. acquired a new position in United Therapeutics during the second quarter valued at approximately $269,000. Institutional investors and hedge funds own 95.85% of the company’s stock.
United Therapeutics stock traded down $0.60 during mid-day trading on Friday, reaching $123.92. 280,025 shares of the company were exchanged, compared to its average volume of 334,292. United Therapeutics Co. has a 12 month low of $100.57 and a 12 month high of $152.55. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. The firm has a market cap of $5.38 billion, a PE ratio of 6.90, a price-to-earnings-growth ratio of 27.85 and a beta of 1.24.
In related news, Director Raymond Dwek sold 3,240 shares of the firm’s stock in a transaction on Friday, June 29th. The stock was sold at an average price of $113.07, for a total transaction of $366,346.80. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher Causey sold 810 shares of the firm’s stock in a transaction on Monday, September 10th. The shares were sold at an average price of $119.00, for a total value of $96,390.00. Following the sale, the director now directly owns 1,555 shares in the company, valued at approximately $185,045. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,100 shares of company stock worth $977,508. Corporate insiders own 8.20% of the company’s stock.
Several brokerages recently commented on UTHR. HC Wainwright reissued a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a research report on Thursday, August 2nd. Wedbush raised their price objective on United Therapeutics from $234.00 to $253.00 and gave the company an “outperform” rating in a research report on Thursday, August 2nd. TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a research report on Thursday, August 16th. Zacks Investment Research raised United Therapeutics from a “hold” rating to a “buy” rating and set a $127.00 price objective for the company in a research report on Saturday, July 7th. Finally, BidaskClub lowered United Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, September 7th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the stock. United Therapeutics currently has an average rating of “Hold” and an average target price of $138.86.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Featured Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.